ClinicalTrials.gg
RecruitingNCT02292641Updated Oct 17, 2024

Beyond TME Origins

An interventional study of New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery in Neoplasms, Adenocarcinoma and Carcinoma, sponsored by Imperial College London. Recruiting at 4 sites in 2 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2024-10-17.

Primary conditionAdenocarcinomaRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Adenocarcinoma
Why
  1. The study's listed conditions name Adenocarcinoma, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Imperial College London · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2014; still recruiting 12 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
383
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 53 studies in Adenocarcinoma with a site in United Kingdom — 9 open to participants now, 15 under way, 5 of them phase 3. Adenocarcinoma · United Kingdom.

Planned enrollment
18th of 49
383 · median 260
Started
2014
with 2 others
No phase
6 of 53
4 open now
Primary completion
2026-12
later than 5 of 14 live
Registered
28th of 53
by date
Lead sponsor
2 of 53
Imperial College London

Among the 53 studies in Adenocarcinoma with a site in United Kingdom, this one is the 18th largest by planned enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2014, is one of 6 with no phase, reaches primary completion later than 5 of the 14 other live ones, and was the 28th registered.

Adenocarcinoma

622 studies on the registry are indexed under Adenocarcinoma; 149 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

9 of the 53 studies in Adenocarcinoma with a site in United Kingdom are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 113 Adenocarcinoma studies recruiting now, 84 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Adenocarcinoma with a site in United Kingdom, or all of them as a file.
02

Study summary

All patients with recurrent colorectal cancer in the pelvis are eligible. The original primary tumour staging scans and resected surgical specimen needs to be available. Patients' recurrence will be staged using our proposed MRI classification. We will be assessing the original primary staging scans and histopathology to learn about risk factors for recurrence. We will record treatment for the recurrence, and patients will be followed up for three years.

Read the detailed description

A prospective and retrospective cohort study to improve surgical and treatment planning using an imaging assessment proforma of advanced and recurrent colorectal cancers. This involves the implementation of imaging assessment proformas describing anatomic pelvic compartments and aetiology of disease recurrence for treatment planning.

03

Conditions studied

  • Neoplasms
  • Adenocarcinoma
  • Carcinoma

Browse trials for

Keywords

  • Lower Gastrointestinal Tract
  • Rectum
  • Diagnostic Imaging
  • Magnetic Resonance Imaging
  • Pelvic Exenteration
  • Neoplasms
  • Adenocarcinoma
  • Carcinoma
04

In context

Adenocarcinoma Reclassified

622 studies on the registry are indexed under Adenocarcinoma; 149 are open to participants now.

This study's planned enrollment of 383 is above the median of 57 across 492 interventional studies indexed under Adenocarcinoma.

Browse Adenocarcinoma studies →

Lead sponsor

Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Compared within Adenocarcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Had a primary colorectal adenocarcinoma proven by taken as part of routine clinical practice
  2. Has a confirmed diagnosis of recurrent pelvic colorectal cancer
  3. Has previously completed surgical treatment of primary adenocarcinoma of the colon, sigmoid colon or rectum
  4. Are able to undergo high resolution MRI for staging prior to treatment decisions
  5. Have provided written to participate in the study
  6. Be aged 16 years or over

Exclusion criteria

Exclusion Criteria:

  1. Have irresectable extra-pelvic disease
  2. Original baseline staging and preoperative restaging scans (MR for rectal and sigmoid cancers and/or CT for colon and sigmoid cancers) are unavailable
  3. Original preoperative, surgical and treatment has not been documented or is unavailable
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
383 participants (estimated)

Study arms

  • Other
    Patients with pelvic recurrence from primary colorectal cancer

    Implementation of imaging assessment proformas describing anatomic pelvic compartments and aetiology of disease recurrence for treatment planning.

    Procedure: New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery

Interventions

  • ProcedureNew Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery

    Currently there are no validated criteria or guidelines for judging whether advanced primary or recurrent colorectal cancer can be successfully removed and for selecting which patients should undergo this form of more radical surgery as is exenterative surgery. We are proposing that by validating the detailed evaluation of imaging of the tumour distribution within the pelvis using a new radiological staging classification, this will enable clear selection criteria to be established and will improve surgical planning.

07

What researchers measure

Primary outcomes

  1. To change R0 resection rates for locally recurrent rectal cancers with the use of the proposed staging system.

    An increase of 20% in R0 resection (from 55% to 75%) for locally recurrent rectal cancers with the use of the proposed staging system

    Time frame: 3 years

Secondary outcomes

  1. To compare baseline prognostic features against type of recurrence

    Correlation of baseline and post treatment prognostic factors on imaging and pathology against type of recurrence.

    Time frame: 3 and 5 years

  2. To compare the MRI type of recurrence against clinical outcomes

    Proportion of patients with survival \>12mths according to type of recurrence as described on MRI

    Time frame: 1, 3 and 5 years

  3. To compare the MRI compartment(s) distribution of recurrence against clinical outcomes

    Proportion of patients with survival \>12mths according to compartment(s) of recurrence as described on MRI

    Time frame: 1, 3 and 5 years

  4. To investigate the effect of surgical and non-surgical treatments for recurrence on Quality of Life

    Quality of life assessed using EORTC QLQ-C30

    Time frame: 1, 2, 3 and 5 years

  5. To compare radiology and histopathology compartments in patients undergoing beyond TME surgery for recurrence

    The number of compartments predicted as involved on MRI against the number of compartments reported on the corresponding pathology specimens

    Time frame: Up to 2 years

  6. To measure radiology inter-observer agreement for types of recurrence classification

    Kappa agreement between paired radiologists for type of recurrence

    Time frame: 5 years

  7. To investigate health economic costs of patients with pelvic recurrence against type

    Healthcare costs using NHS Reference Costs combined with health resource utilization and QoL data

    Time frame: Up to 3 years

  8. To map original radiotherapy volumes (including integrated boosts) against types of recurrence

    Correlation of dose, type and distribution of radiotherapy against anatomic sites and aetiology of recurrence as seen on MRI

    Time frame: Up to 2 years

08

Study locations

4 of 4 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2014 (actual). Primary completion is estimated for Dec 2026, 147 months after the start.

Of 41 interventional studies with no phase under Adenocarcinoma, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 170. This study's planned 147 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2014
First posted
Nov 17, 2014
StartActual
Sep 25, 2014
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2031
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02292641
Collaborators
Pelican Cancer Foundation
Responsible party
Sponsor
First posted
Nov 17, 2014
Start date
Sep 25, 2014
Primary completion
Dec 2026 (estimated)
Completion
Dec 2031 (estimated)
Last update
Oct 17, 2024

Study contacts

Caroline Martin
Contact
c.martin1@imperial.ac.uk
+44 (0) 7749 655 817
Syvella Ellis
Contact
giclinicaltrials@imperial.ac.uk
+44 (0) 7732 315 234
Gina Dr Brown, MD
principal investigator · Imperial College London

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion